Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1

被引：0

作者：

Besse, Benjamin ^{[1
]}

Le Moulec, Sylvestre ^{[2
]}

Mazieres, Julien ^{[3
]}

Pouessel, Damien ^{[4
]}

Alberts, Istvan ^{[5
]}

Romano, Giampiero ^{[6
]}

Girard, Nicolas ^{[7
]}

Pichon, Eric ^{[8
]}

Molinier, Olivier ^{[9
]}

Chouaid, Christos ^{[10
]}

Corre, Romain ^{[11
]}

Remon, Jordi ^{[12
]}

Dziadziuszko, Rafal ^{[13
]}

Felip, Enriqueta ^{[14
]}

Giaccone, Giuseppe ^{[15
]}

机构：

[1] Gustave Roussy, Dept Canc Med, Villejuif, France

[2] Inst Bergonie, Bordeaux, France

[3] Toulouse Univ Hosp, Dept Pulmonol, Toulouse, France

[4] Hop St Louis, AP HP, Paris, France

[5] Matrai Gyogyint, Matrahaza, Hungary

[6] Osped V Fazzi, Lecce, Italy

[7] Louis Pradel Hosp, Lyon, France

[8] Univ Hosp, Tours, France

[9] Hosp Ctr, Le Mans, France

[10] Chi Creteil, Pulmonol, Creteil, France

[11] CHU Rennes, Rennes, France

[12] Gustave Roussy, Dept Med Oncol, Paris, France

[13] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland

[14] Hosp Univ Vall DHebron, Barcelona, Spain

[15] Lombardi Canc Ctr, Oncol, Washington, DC USA

来源：

关键词：

non-small cell lung cancer; Second-line; HLA-A2; TEDOPI;

D O I：

10.1016/j.jtho.2016.11.1517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.06-024

引用

页码：S1085 / S1086

页数：2